Skip to content

Effect of Probiotic Intake on Improvement of Higher Cerebral Function in Participants with Suspected Mild Cognitive Impairment

Effect of Probiotic Intake on Improvement of Higher Cerebral Function in Participants with Suspected Mild Cognitive Impairment - Effect of Probiotic on Participants with Suspected Mild Cognitive Impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031679
Enrollment
120
Registered
2018-04-04
Start date
2018-03-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

Sponsors

HUMA R&D CORP
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age:50 and over, below 80. 2) Sex:Males and females with Japanese nationality. 3) Subjects whose MMSE score is 22 to 27.

Exclusion criteria

Exclusion criteria: 1) Subjects who are under medication or treatment for serious disease. 2) Subjects who are under diet therapy and exercise therapy in the control of doctor. 3) Subjects with a history of liver disease or serious renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological and metabolic diseases or those who undertake medication or treatment for such disease. 4) Subjects having a history of major surgery involving gastrectomy, gastrointestinal suture surgery, bowel resection, digestive system etc. (except fo rappendicitis) 5) Subjects with a current or past history of psychiatric disorders. 6) Subjects with a current or past history of drug or food allergy. 7) Subjects who are diagnosed as dementia. 8) Subjects who are receiving or have a history of drug dependence or drug abuse. 9) Subjects who have participated in other clinical tests within the past one months. 10) Subjects with irregular working hours, such as night shifts. 11) Subjects with a current or past history of alcoholism. 12) Subjects who were judged inadequate by investigator for other reasons.

Design outcomes

Primary

MeasureTime frame
RBANS MMSE

Secondary

MeasureTime frame
POMS2(Short Form) Patient Health Questionnaire-9 (PHQ-9)

Countries

Japan

Contacts

Public ContactMatsuoka Masao

HUMA R&D CORP Clinical Development Division

matsuoka@huma-c.co.jp03-3431-1260

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026